Table 3

Description of the characteristics of the individuals included in the cohort, their median time spent in disability, the rate of those experiencing one of the three competing events and the rate of those remaining work disabled after 3 years of follow-up

n=15 543Total individualsMedian time spent in work disability (years) (CI 95%)3-year cumulative probability of ending work disabilityWork disability
(censored)
n (%)DeathRetirementAbility to work
Year of entry
 20073454 (22.2)1.89 (1.780 to 2.048)29.04 (27.52–30.55)1.51 (1.10–1.91)28.69 (27.18–30.20)40.76 (36.74–44.78)
 20083760 (24.2)1.83 (1.717 to 1.960)28.64 (27.20–30.09)1.65 (1.24–2.06)30.13 (28.67–31.60)39.57 (35.62–43.52)
 20093630 (23.4)1.76 (1.621 to 1.889)28.76 (27.29–30.23)0.74 (0.46–1.02)30.61 (29.11–32.11)39.89 (35.90–43.88)
 20103388 (21.8)1.54 (1.410 to 1.670)27.54 (26.03–29.04)0.56 (0.31–0.81)32.29 (30.72–33.86)39.61 (35.45–43.77)
 20111311 (8.4)0.45 (0.413 to 0.487)31.59 (29.01–34.17)0.54 (0.14–0.93)46.76 (44.04–49.47)21.12 (10.23–32.00)
Age at entry
 17–392421 (15.6)1.51 (1.415 to 1.69)18.46 (16.91–20.00)45.53 (43.54–47.52)36.01 (30.69–41.33)
 40–495052 (32.5)1.76 (1.637 to 1.88)22.74 (21.59–23.90)36.17 (34.84–37.49)41.09 (37.78–44.39)
 50–596946 (44.7)1.70 (1.580 to 1.79)34.21 (33.10–35.33)25.51 (24.48–26.53)40.28 (37.41–43.15)
 ≥601121 (7.2)0.91 (0.797 to 1.06)44.19 (41.28–47.10)14.95 (12.86–17.04)21.51 (19.10–23.92)19.34 (7.36–31.33)
Gender
 Male5874 (38)1.18 (1.12 to 1.26)43.52 (42.26–44.79)1.5 (1.19–1.82)23.15 (22.08–24.23)31.82 (28.07–35.57)
 Female9669 (62)1.94 (1.84 to 2.05)19.78 (18.98–20.57)0.82 (0.64–1.00)37.06 (36.09–38.02)42.35 (40.02–44.67)
Occupational class
 Blue collar7715 (50)1.79 (1.72 to 1.89)31.43 (30.39–32.46)0.59 (0.42–0.76)26.65 (25.66–27.63)41.34 (38.68–44.00)
 White collar5703 (37)1.30 (1.23 to 1.37)24.46 (23.34–25.57)0.63 (0.43–0.84)40.74 (39.47–42.02)34.17 (30.56–37.78)
 Assisting spouse and self-employed2125 (13)1.79 (1.63 to 1.97)30.56 (28.60–32.53)4.08 (3.24–4.92)26.53 (24.66–28.41)38.82 (33.47–44.18)
Cancer site
 CIS/Benign614 (4)4.98 (3.24 to 6.72)10.76 (8.31–13.21)1.14 (0.30–1.98)33.07 (29.35–36.79)55.03 (47.87–62.18)
 Head and neck877 (5.6)1.69 (1.41 to 1.93)44.43 (41.14–47.73)0.35 (0.00–0.74)17.69 (15.17–20.22)37.53 (28.97–46.08)
 Digestive tract2400 (15.4)1.31 (1.18 to 1.41)42.15 (40.18–44.13)1.76 (1.23–2.28)23.98 (22.27–25.69)32.11 (26.29–37.94)
 Respiratory tract1417 (9.1)0.75 (0.69 to 0.83)69.91 (67.52–72.30)0.86 (0.37–1.34)9.47 (7.94–10.99)19.77 (9.26–30.28)
 Haematological1660 (10.7)1.83 (1.66 to 2.08)20.56 (18.62–22.51)0.91 (0.45–1.36)37.39 (35.06–39.72)41.14 (35.38–46.90)
 Breast5511 (35.0)2.10 (1.95 to 2.30)10.29 (9.49–11.09)0.78 (0.55–1.02)44.80 (43.49–46.12)44.13 (41.15–47.10)
 Female genital organs821 (5.3)1.56 (1.37 to 1.82)34.50 (31.25–37.76)0.12 (0.00–0.36)28.76 (25.67–31.86)36.61 (27.60–45.62)
 Male genital organs486 (3.1)1.73 (1.52 to 2.24)17.93 (14.52–21.35)6.21 (4.06–8.36)36.25 (31.97–40.53)39.60 (28.60–50.61)
 Urinary tract388 (2.5)1.67 (1.32 to 2.16)38.19 (33.35–43.03)1.55 (0.32–2.78)21.39 (17.31–25.47)38.86 (26.37–51.36)
 CNS709 (4.6)1.46 (1.18 to 1.89)45.92 (42.25–49.60)0.42 (0.00–0.90)16.23 (13.52–18.95)37.42 (27.88–46.96)
 Bone and connective tissue (sarcomas)/skin/thyroid660 (4.2)1.24 (1.03 to 1.52)39.13 (35.40–42.86)0.76 (0.10–1.42)26.55 (23.18–29.92)33.56 (22.81–44.31)
Total, n (%)15 5431.59 (1.52 to 1.66)4468 (29%)167 (1%)4943 (32%)5964 (38%)
  • CIS, carcinoma in situ; CNS, central nervous system.